UNITED THERAPEUTICS CORPORATION Environmental Analytics
Environmental and financial analysis dashboard for UNITED THERAPEUTICS CORPORATION. Industry: MANUFACTURING
Company Overview for UNITED THERAPEUTICS CORPORATION
Highlights
Showing data for FY2022
Operational Environmental Cost
$25m
Operational Environmental Cost Intensity
1.28%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$13m
Decoupling Rate (2020-2022)
-29%
Adjusted EBITDA
$1,009m
Adjusted EBITDA Margin
52%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 45.95% | 34.66% | 42.61% | ||
| 0.28% | 0.36% | 0.42% | 0.50% | |
| 68.29% | 36.52% | 54.42% | ||
| 0.49% | 0.73% | 0.87% | 1.11% | |
| $11m | $18m | $25m | $37m | |
| 60.22% | 35.91% | 50.57% | ||
| 0.77% | 1.09% | 1.28% | 1.61% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
52%
Adjusted EBIT Margin
49%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$1,483m | $1,686m | $1,936m | $2,328m | |
| 13.63% | 14.88% | 20.20% | ||
$771m | $1,023m | $902m | $941m | |
| 51.98% | 60.70% | 46.58% | 40.42% | |
$712m | $662m | $1,034m | $1,387m | |
| 48.02% | 39.30% | 53.42% | 59.58% | |
$662m | $613m | $983m | $1,334m | |
| 44.66% | 36.34% | 50.77% | 57.30% | |
| ENVIRONMENTAL COST DATA | ||||
$11m | $18m | $25m | $37m | |
| 0.77% | 1.09% | 1.28% | 1.61% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$701m | $644m | $1,009m | $1,349m | |
| 47.25% | 38.21% | 52.13% | 57.97% | |
$651m | $594m | $958m | $1,296m | |
| 43.89% | 35.25% | 49.48% | 55.69% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.42%
Scope 2 (% of Sales)
0.87%
Operational Environmental Cost Intensity
1.28%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
UNITED THERAPEUTICS CORPORATION | US | $25m | 1.28% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022